BRPI0913410A2 - uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica - Google Patents

uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Info

Publication number
BRPI0913410A2
BRPI0913410A2 BRPI0913410A BRPI0913410A BRPI0913410A2 BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2 BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A BRPI0913410 A BR PI0913410A BR PI0913410 A2 BRPI0913410 A2 BR PI0913410A2
Authority
BR
Brazil
Prior art keywords
nanoparticle
pharmaceutical composition
aggregate
nanoparticle aggregate
pharmaceutical
Prior art date
Application number
BRPI0913410A
Other languages
English (en)
Inventor
Agnès Pottier
Annabelle Rouet
Corinne Devaux
Julie Marill
Laurent Levy
Matthieu Germain
Original Assignee
Nanobiotix
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanobiotix filed Critical Nanobiotix
Publication of BRPI0913410A2 publication Critical patent/BRPI0913410A2/pt
Publication of BRPI0913410B1 publication Critical patent/BRPI0913410B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/244—Lanthanides; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Radiation-Therapy Devices (AREA)
  • Medicinal Preparation (AREA)
  • Compounds Of Alkaline-Earth Elements, Aluminum Or Rare-Earth Metals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0913410-7A 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica BRPI0913410B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP08157686A EP2130553A1 (en) 2008-06-05 2008-06-05 Inorganic nanoparticles of high density to destroy cells in-vivo
EP08157686.0 2008-06-05
US6020208P 2008-06-10 2008-06-10
US61/060202 2008-06-10
PCT/EP2009/056880 WO2009147214A2 (en) 2008-06-05 2009-06-04 Inorganic nanoparticles, preparation and uses thereof

Publications (2)

Publication Number Publication Date
BRPI0913410A2 true BRPI0913410A2 (pt) 2015-11-24
BRPI0913410B1 BRPI0913410B1 (pt) 2021-09-21

Family

ID=39734334

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0913410-7A BRPI0913410B1 (pt) 2008-06-05 2009-06-04 Uso de uma nanopartícula ou agregado de nanopartícula, e, composição farmacêutica

Country Status (26)

Country Link
US (1) US8845507B2 (pt)
EP (4) EP2130553A1 (pt)
JP (1) JP5734181B2 (pt)
KR (1) KR101639281B1 (pt)
CN (1) CN102056628B (pt)
AU (1) AU2009254550B2 (pt)
BR (1) BRPI0913410B1 (pt)
CA (1) CA2727576C (pt)
CY (2) CY1118217T1 (pt)
DK (2) DK2300054T3 (pt)
EA (1) EA023012B1 (pt)
ES (2) ES2602048T3 (pt)
HR (2) HRP20161465T8 (pt)
HU (2) HUE030669T2 (pt)
IL (1) IL209625A (pt)
LT (2) LT3150227T (pt)
MA (1) MA32453B1 (pt)
MX (1) MX2010013322A (pt)
NZ (1) NZ589888A (pt)
PL (2) PL2300054T3 (pt)
PT (2) PT2300054T (pt)
SG (1) SG10201405288WA (pt)
SI (2) SI2300054T1 (pt)
TR (1) TR201819077T4 (pt)
WO (1) WO2009147214A2 (pt)
ZA (1) ZA201100082B (pt)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070164238A1 (en) * 2003-02-24 2007-07-19 Pomper Mark E Mobile radiation treatment vehicle and method
US8459714B2 (en) 2006-05-19 2013-06-11 Breya, Llc. Mobile radiation therapy
US8657354B2 (en) 2006-05-19 2014-02-25 Breya, Llc. Mobile radiation therapy
US9232618B2 (en) 2007-08-06 2016-01-05 Immunolight, Llc Up and down conversion systems for production of emitted light from various energy sources including radio frequency, microwave energy and magnetic induction sources for upconversion
US9399075B2 (en) 2008-12-29 2016-07-26 General Electric Company Nanoparticle contrast agents for diagnostic imaging
US8728440B2 (en) 2012-08-23 2014-05-20 General Electric Company Nanoparticulate compositions for diagnostic imaging
US9585840B1 (en) 2009-07-10 2017-03-07 University Of Central Florida Research Foundation, Inc. Redox active cerium oxide nanoparticles and associated methods
EP2275137A1 (en) 2009-07-10 2011-01-19 Nanobiotix Metallic nanoparticles, preparation and uses thereof
CN105931696B (zh) * 2010-04-23 2017-07-07 皮瑟莱根特科技有限责任公司 纳米晶体的合成、盖帽和分散
JP2014503446A (ja) 2010-10-27 2014-02-13 ピクセリジェント・テクノロジーズ，エルエルシー ナノ結晶の合成、キャップ形成および分散
US9359689B2 (en) 2011-10-26 2016-06-07 Pixelligent Technologies, Llc Synthesis, capping and dispersion of nanocrystals
HK1203353A1 (en) 2011-12-16 2015-10-30 Nanobiotix Nanoparticles comprising metallic and hafnium oxide materials, preparation and uses thereof
EP2877212A4 (en) * 2012-06-14 2016-04-27 Univ Arkansas COMPOSITIONS AND METHODS FOR NONINVASIVE DETECTION AND TREATMENT OF HYPOXIC CELLS IN VIVO
US8821838B2 (en) 2012-08-23 2014-09-02 General Electric Company Nanoparticulate compositions for diagnostic imaging
UA116007C2 (uk) * 2013-01-25 2018-01-25 Нанобіотікс Композиції неорганічних наночастинок у комбінації з іонізуючим випромінюванням для лікування раку
WO2014130429A2 (en) * 2013-02-19 2014-08-28 National Health Research Institutes Caged platinum nanoclusters for anticancer chemotherapeutics
UA116380C2 (uk) 2013-05-30 2018-03-12 Нанобіотікс Посилення терапевтичної або профілактичної ефективності фармацевтичної сполуки
EA201690050A1 (ru) 2013-06-20 2016-05-31 Нанобиотикс Композиции и способы для применения в медицинской диагностике
CA2928952A1 (en) * 2013-12-16 2015-06-25 Genentech, Inc. Peptidomimetic compounds and antibody-drug conjugates thereof
EP2886128A1 (en) * 2013-12-20 2015-06-24 Nanobiotix Pharmaceutical composition comprising nanoparticles, preparation and uses thereof
TW201628656A (zh) 2014-11-25 2016-08-16 奈諾生技公司 醫藥組合物、其製備與用途
JP6836510B2 (ja) 2014-11-25 2021-03-03 キュラディグム・エスアエスＣｕｒａｄｉｇｍ Ｓａｓ 少なくとも２つの異なるナノ粒子と医薬化合物とを組み合わせた医薬組成物、その調製及び使用
HUE056175T2 (hu) 2014-11-25 2022-01-28 Curadigm Sas Gyógyászati készítmények, elõállításuk és alkalmazásaik
HK1245086A1 (zh) 2014-11-25 2018-08-24 Nanobiotix 处方药物组成及其制备和使用
WO2016083331A1 (en) 2014-11-25 2016-06-02 Nanobiotix Pharmaceutical composition, preparation and uses thereof
EP3242670B1 (en) * 2015-01-08 2020-06-24 Purdue Research Foundation Non-toxic formulations of radio-luminescent nanoparticles for use as cancer radio-sensitizing agents
US11096962B2 (en) * 2015-05-28 2021-08-24 Nanobiotix Nanoparticles for use as a therapeutic vaccine
US11389536B2 (en) 2015-07-17 2022-07-19 BioCurity Pharmaceuticals Inc. Treatment of cancer with a combination of radiation, cerium oxide nanoparticles, and a chemotherapeutic agent
CN109010828B (zh) * 2018-10-12 2020-10-20 中国科学院高能物理研究所 一种二硫化钼/二氧化铪的复合纳米材料、其制备方法及用途
CN109616308B (zh) * 2018-11-07 2020-09-04 湖北第二师范学院 一种球形纳米氧化铱dna提取磁性粉末及其生产方法
CN109771645B (zh) * 2019-03-07 2021-08-24 广西师范大学 一种二氧化钌复合卵清蛋白纳米材料的制备及其应用
WO2021239730A1 (en) * 2020-05-26 2021-12-02 Nanobiotix Nanoparticles, ionizing radiation and innovative therapeutic combinations thereof
IL302571A (en) * 2020-11-05 2023-07-01 Nanobiotix Compositions of nanoparticles for treatment of cancer
WO2022117529A1 (en) * 2020-12-01 2022-06-09 Nanobiotix Porous, high-z and carbon-free particles as radioenhancers
KR20250149955A (ko) 2022-12-12 2025-10-17 나노비오띡스 방사선증강제로서 사용하기 위한 또는 생물학적 조직 시각화를 위한 신규한 금속 산화물 나노입자 및 이의 조성물
EP4595983A1 (en) 2024-02-05 2025-08-06 BXTA Nanotherapy Limited Nanoparticles functionalised with a stabilising agent and a targeting agent
WO2026074471A1 (en) * 2024-10-02 2026-04-09 Janssen Pharmaceutica Nv Combination therapies with hafnium oxide nanoparticles and pd-l1 antibodies for use in the treatment of non small cell lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6287526A (ja) * 1985-10-11 1987-04-22 Akira Fujishima 抗腫瘍剤
WO2000006244A2 (en) 1998-07-30 2000-02-10 Hainfeld James F Loading metal particles into cell membrane vesicles and metal particle use for imaging and therapy
EP1696957A2 (en) 2003-12-17 2006-09-06 Philips Intellectual Property & Standards GmbH Radiation therapy and medical imaging using uv emitting nanoparticles
FR2869803B1 (fr) 2004-05-10 2006-07-28 Nanobiotix Sarl Particules activables, preparation et utilisations
US20070092927A1 (en) * 2005-06-13 2007-04-26 University Of Dayton Photocatalytic particles with directed and controlled redox activity
JP2007075696A (ja) * 2005-09-13 2007-03-29 Mitsubishi Materials Corp 多孔質光触媒膜
RU2009104312A (ru) * 2006-07-10 2010-08-20 Конинклейке Филипс Электроникс Н.В. (Nl) Наночастицы типа "ядро-оболочка" для терапии и диагностических целей
EP1920784A1 (en) * 2006-11-13 2008-05-14 Koninklijke Philips Electronics N.V. Radiation sensitizers in ionizing radiation therapy and imaging

Also Published As

Publication number Publication date
IL209625A (en) 2015-11-30
HUE030669T2 (en) 2017-05-29
HUE040247T2 (hu) 2019-02-28
JP5734181B2 (ja) 2015-06-17
TR201819077T4 (tr) 2019-01-21
NZ589888A (en) 2012-06-29
AU2009254550B2 (en) 2013-10-24
HRP20161465T1 (hr) 2017-01-27
CY1121078T1 (el) 2019-12-11
EA023012B1 (ru) 2016-04-29
EP3461502A1 (en) 2019-04-03
KR101639281B1 (ko) 2016-07-13
EP2130553A1 (en) 2009-12-09
EP3150227B1 (en) 2018-10-31
PT3150227T (pt) 2018-12-24
WO2009147214A3 (en) 2010-02-25
EP2300054B1 (en) 2016-09-07
PL3150227T3 (pl) 2019-05-31
US8845507B2 (en) 2014-09-30
CN102056628A (zh) 2011-05-11
AU2009254550A1 (en) 2009-12-10
BRPI0913410B1 (pt) 2021-09-21
MX2010013322A (es) 2011-01-21
MA32453B1 (fr) 2011-07-03
HRP20181993T1 (hr) 2019-01-25
ES2602048T3 (es) 2017-02-17
SI2300054T1 (sl) 2017-02-28
US20110213192A1 (en) 2011-09-01
DK3150227T3 (en) 2019-01-14
HRP20161465T8 (hr) 2017-04-21
CA2727576A1 (en) 2009-12-10
SI3150227T1 (sl) 2019-02-28
EA201071429A1 (ru) 2011-06-30
SG10201405288WA (en) 2014-10-30
CY1118217T1 (el) 2017-06-28
PL2300054T3 (pl) 2017-04-28
LT2300054T (lt) 2016-12-27
ZA201100082B (en) 2011-10-26
CN102056628B (zh) 2013-07-10
CA2727576C (en) 2016-08-16
ES2702249T3 (es) 2019-02-28
WO2009147214A2 (en) 2009-12-10
EP2300054A2 (en) 2011-03-30
DK2300054T3 (en) 2016-12-05
JP2011524866A (ja) 2011-09-08
IL209625A0 (en) 2011-02-28
EP3150227A1 (en) 2017-04-05
KR20110028616A (ko) 2011-03-21
LT3150227T (lt) 2018-12-10
PT2300054T (pt) 2016-11-11

Similar Documents

Publication Publication Date Title
BRPI0917001A2 (pt) composto, composição farmacêutica, e, uso de um composto ou uma composição farmacêutica
BRPI0917315A2 (pt) anticorpo, composicao farmaceutico, e, uso de uma composicao farmaceutica
LTPA2018014I1 (lt) Farmacinė kompozicija 514
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0912717A2 (pt) Composição farmacêutica, e, uso de 5-azacitidina
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0813770A2 (pt) Composição, e, uso de uma composição
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI1008039A2 (pt) composto, mistura, composição farmacêutica, e, uso de um coposto, de uma mistura ou de uma composição farmacêutica
BR112013001571A2 (pt) composto, composição farmacêutica, uso e método de prevenção ou tratamento de uma condição associada com a função do receptor gpr40
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0910557A2 (pt) composições farmacêuticas de paclitaxel, análogos de paclitaxel ou conjugados de paclitaxel e métodos relacionados de preparação e uso.
BRPI1005931A8 (pt) associação de compostos, uso de uma associação, produto em forma de kit, uso de um produto e composição farmacêutica
BRPI0816350A2 (pt) Composições orais, produtos e métodos de uso
BRPI0914793A2 (pt) Composição, e, uso de uma composição
BRPI1013421A2 (pt) composição parasticida tópica, e, uso de uma composição
BRPI1014316A2 (pt) composição, e, uso de uma composição
BRPI0918206A2 (pt) derivados de animoéster e composição medicinal destes
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI1006953A2 (pt) composição farmacêutica, e, uso de uma composição
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0920355A2 (pt) composições farmacêuticas tópicas estáveis de ozenoxacina e uso de ozenoxacina
BRPI0813587A2 (pt) Composto, uso do mesmo, e, composição farmacêutica

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 04/06/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.